Background: Airway inflammation in asthma involves both large and small airways, and the combination of inhaled corticosteroids (ICS) and long acting beta-2 agonists (LABA) is the mainstay of therapy. Available inhaled combinations differ in terms of drug delivery to the lung and the ability to reach small airways.
Aim: To evaluate whether treatment with an extra-fine inhaled combination provides additional effects vs a nonextra-fine combination on airway function.
Methods: After a 1- to 4-week run-in period, patients with asthma were randomized to a double blind, double dummy, 12-week treatment with either extra-fine beclomethasone/formoterol (BDP/F) 400/24 microg daily or fluticasone propionate/salmeterol (FP/S) 500/100 microg daily. Methacholine (Mch) bronchoprovocation challenge and single breath nitrogen (sbN2) test were performed.
Results: Thirty patients with asthma (15 men), mean age 43, mean forced expiratory volume in the first second (FEV(1)) 71.4% of predicted, were included. A significant increase (P < 0.01) versus baseline was observed in predose FEV(1) in both BDP/F and FP/S groups (0.37 +/- 0.13 l and 0.36 +/- 0.12 l, respectively). PD(20)FEV(1) Mch improved significantly from 90.42 (+/-30.08) microg to 432.41 (+/-122.71) microg in the BDP/F group (P = 0.01) but not in the FP/S group. A trend toward improvement vs baseline was observed for BDP/F in closing capacity (CC), whereas no differences were recorded in other sbN(2) test parameters.
Conclusion: The findings of this pilot study suggest that an extra-fine inhaled combination for the treatment of asthma has beneficial effects on both large and small airways function as expressed by Mch and sbN(2) tests.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1398-9995.2009.02306.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Annual research progress in chronic obstructive pulmonary disease 2024].
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Hetao Institute of Guangzhou National Laboratory, Shenzhen518000, China.
Article Synopsis
- COPD is a growing global health issue, with recent advancements in early detection and personalized treatment, highlighting the importance of monitoring early-stage disease for better prognosis.
- Research has identified critical areas in the lungs as initial sites of damage, and specific biomarkers may help track different disease progression patterns.
- New treatment strategies, including triple inhalation therapy and innovative medications, show promise in managing symptoms and improving patient outcomes in COPD, with ongoing research aimed at understanding disease variability.
Evaluating the Role of Maximal Expiratory Flow at 25% (MEF-25) in Detecting and Managing Patients With Small Airway Disease in the United Arab Emirates.
Cureus
November 2024
Department of Pulmonary Medicine, King's College Hospital, Dubai, ARE.
Middle Eastern countries, such as the United Arab Emirates and Oman, are affected by frequent dust storms and extreme hot climatic conditions, which can exacerbate respiratory conditions. These environmental factors are particularly injurious to asthmatic patients, as they can aggravate small airway disease (SAD), leading to increased morbidity and healthcare challenges. The evaluation of maximal mid-expiratory flow (MEF-25) as a diagnostic and therapeutic tool for early-stage small airway dysfunction is of significant clinical importance, particularly in hot and arid metropolitan environments where dusty conditions exacerbate pulmonary issues.
View Article and Find Full Text PDF[Real-life utilization of fixed triple therapy in COPD: The Trilife study. Beclomethasone/formoterol/glycopyrronium triple fixed-dose therapy in extra-fine particles].
Rev Mal Respir
December 2024
VIM Suresnes-UMR-0892, université Paris Saclay, hôpital Foch, Suresnes, France.
Introduction: The Trilife study describes the real-life use, in France, of the beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in solution for inhalation, which is indicated as continuous treatment for moderate-to-severe chronic obstructive pulmonary disease.
Methods: This prospective, non-interventional, multicentric study, involving hospital and office-based pulmonologists, evaluates the proportion of patients for whom the triple fixed combination was prescribed in compliance with the indication and dosage specified in the summary of product characteristics (SPC). Patients were followed for six months.
Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study.
Int J Chron Obstruct Pulmon Dis
October 2024
Section of Respiratory Medicine, Department of Medicine, Copenhagen University Hospital Herlev and Gentofte, Hellerup, Denmark.
Article Synopsis
- A study compared the effects of extra-fine particle inhaled corticosteroids (ICS) to standard particle size ICS on patients with chronic obstructive pulmonary disease (COPD) from 2010 to 2017, focusing on exacerbations needing hospitalization and overall mortality rates.
- Of the nearly 40,500 patients analyzed, the results showed that extra-fine particle ICS did not significantly lower the risk of hospitalizations or all-cause mortality compared to standard ICS; however, a subgroup of patients using pressurized metered dose inhalers (pMDIs) did report reduced risks.
- The findings suggest that while extra-fine particle ICS may not generally offer protective benefits, they could be beneficial for specific patients
Dandelion inspired microparticles with highly efficient drug delivery to deep lung.
Colloids Surf B Biointerfaces
December 2024
Suzhou Key Laboratory of Green Chemical Engineering, School of Chemical and Environmental Engineering, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, Jiangsu Province 215123, PR China. Electronic address:
Active pharmaceutical ingredient (API) embedded dry powder for inhalation (AeDPI) shows higher drug loading and delivery dose for directly treating various lung infections. Inspired by the dandelion, we propose a novel kind of AeDPI microparticle structure fabricated by spray freeze drying technology, which would potentially enhance the alveoli deposition efficiency. When inhaling, such microparticles are expected to be easily broken-up into fragments containing API that acts as 'seed' and could be delivered to alveoli aided by the low density 'pappus' composed of excipient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!